Vicore Pharma to Participate in the Guggenheim Annual Healthcare Innovation Conference and the Stifel Healthcare Conference

Vicore Pharma (VCRE) will participate in the Guggenheim healthcare conference on November 9 and the Stifel healthcare conference on November 12, 2026.

Rhea-AI Summary

Vicore Pharma (VCRE) will participate in the Guggenheim healthcare conference on November 9 and the Stifel healthcare conference on November 12, 2026. CEO Ahmed Mousa will hold a fireside chat in Boston from 8:00–8:25 AM ET at Guggenheim and present in New York from 10:40–11:10 AM ET at Stifel. Both events include one-on-one meetings.

Key Terms

angiotensin ii type 2 receptor agonist, orphan drug designation, fast track designation, idiopathic pulmonary fibrosis

4 terms

angiotensin ii type 2 receptor agonist medical

"a biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists"

A molecule that binds to and activates the angiotensin II type 2 receptor (AT2R), a specific protein on cell surfaces that triggers biological pathways involved in blood vessel tone, inflammation, tissue repair and organ protection. Think of the receptor as a lock and the agonist as a key that turns it on to produce a cellular response. These drugs matter to investors because they represent a category of therapeutic candidates with potential clinical and commercial impact in cardiovascular, renal and fibrotic conditions.

orphan drug designation regulatory

"which received Orphan Drug and Fast Track designations"

Orphan drug designation is a special status given to medicines developed to treat rare diseases affecting only a small number of people. This status often provides benefits like faster approval processes and financial incentives, making it more attractive for companies to develop these drugs. For investors, it signals potential for exclusive market rights and reduced competition, which can impact the drug’s profitability.

fast track designation regulatory

"which received Orphan Drug and Fast Track designations"

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

idiopathic pulmonary fibrosis medical

"including idiopathic pulmonary fibrosis (IPF)"

Idiopathic pulmonary fibrosis is a chronic lung disease in which the air‑carrying tissue becomes progressively thickened and scarred for no identifiable reason, making the lungs stiff and less able to move oxygen—similar to a sponge that hardens and loses its pores. It matters to investors because it is life‑limiting with limited effective treatments, so clinical trial outcomes, regulatory approvals, pricing and reimbursement decisions can strongly affect the commercial value of therapies and the financial prospects of companies developing treatments.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

STOCKHOLM, SE / ACCESS Newswire / November 2, 2026 / Vicore Pharma Holding AB (STO:VICO)(NASDAQ:VCRE), a biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, today announced that the company will participate in the following upcoming healthcare conferences:

Guggenheim 3^rd Annual Healthcare Innovation Conference

• Location: InterContinental Boston, Boston
• Format: Fireside chat and 1×1 meetings
• Date and time: Monday, November 9, 2026, 8:00-8:25 AM ET
• Participant: Ahmed Mousa, Chief Executive Officer
• Webcast: Link

Stifel 2026 Healthcare Conference

• Location: Lotte New York Palace, New York
• Format: Presentation and 1×1 meetings
• Date and time: Thursday, November 12, 2026, 10:40-11:10 AM ET
• Participant: Ahmed Mousa, Chief Executive Officer
• Webcast: Link

For further information, please contact:
Hans Jeppsson, Chief Financial Officer, +46 (0)70 553 14 65, hans.jeppsson@vicorepharma.com

About Vicore Pharma Holding AB
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, including idiopathic pulmonary fibrosis (IPF). The company's lead program, buloxibutid, is an oral small-molecule angiotensin II type 2 receptor agonist, which received Orphan Drug and Fast Track designations from the United States Food and Drug Administration and is currently being investigated in the global 52-week Phase 2b ASPIRE trial in IPF. Vicore Pharma is publicly listed on Nasdaq Stockholm (VICO) and Nasdaq US (VCRE). www.vicorepharma.com

Attachments
Vicore Pharma to Participate in the Guggenheim Annual Healthcare Innovation Conference and the Stifel Healthcare Conference

SOURCE: Vicore Pharma Holding

View the original press release on ACCESS Newswire